

# Florida Department of Health

## FLORIDA'S BIOMEDICAL RESEARCH ADVISORY COUNCIL UPDATE- MAY 2023

Richard Nowakowski, PhD  
Vice Chair, Florida Biomedical  
Research Advisory Council



# Biomedical Research Advisory Council

- **Daniel Armstrong, Ph.D. (Chair)**  
**University of Miami Miller School of Medicine**  
**Seat: American Cancer Society**
  - **Richard Nowakowski, Ph.D. (Vice Chair)**  
**Florida State University College of Medicine**  
**Seat: Governor**
  - **Charles Evans Wood, Ph.D.**  
**University of Florida**  
**Seat: American Heart Association**
  - **David A. Decker, M.D., F.A.C.P.**  
***Recently Retired***  
**Seat: Governor**
  - **Tushar Patel, M.B., Ch.B.**  
**Mayo Clinic Jacksonville**  
**Senate – Cancer Program (ACoS)**
  - **Allison Eng-Perez**  
**Deloitte and Touche**  
**Seat: Governor**
  - **Richard A. Houghten, Ph.D.**  
**Torrey Pines Institute for Molecular Studies**  
**Seat: Senate**
  - **Guilherme Oliveira, MD, MBA**  
**Tampa General Hospital, University of South Florida**  
**Seat: House of Representatives**
- Vacant seats:**
1. Governor
  2. House of Representatives
  3. American Lung Association

# Current Funding and Active Grants

***ANTICIPATED- FUNDING OPPORTUNITY ANNOUNCEMENT WILL BE RELEASED  
BY MAY 31<sup>st</sup> PENDING SIGNED GAA***

## James and Esther King Biomedical Research Program

- \$7.85 million available to award research grants in Fiscal Year 2023-2024  
Proceeds from the Lawton Chiles Endowment Funds ended June 2022

## Bankhead-Coley Cancer Research Program

- \$10 million available to award research grants in Fiscal Year 2023-2024  
(Includes \$500,000 appropriated annually to the McKnight Brain Institute paid for through this fund)

## Live Like Bella Pediatric Cancer Research Initiative

- \$3 million available to award research grants in Fiscal Year 2023-2024

# Direct Appropriations

## Casey DeSantis Cancer Research Program- Funding for Florida-based cancer centers recognized by the National Cancer Institute

- \$127.5 million **planned** for July 1, 2023. Plus \$500,000 to be used for comprehensive strategic planning.
- New Requirements:
  - All cancer centers receiving funding under the Casey DeSantis Cancer Research Program shall submit quarterly to the Florida Cancer Data System, data on new cancer diagnoses and cancer recurrence.
  - All funded cancer centers shall submit quarterly, data on patient outcomes by cancer type and mortality and survival rates for patients treated.
  - The Department of Health will develop a long-range plan on implementing the legislative intent.

# FUNDING CYCLE AWARDS FOR FISCAL YEAR 22-23

**28 Awards – Prevention and Treatment: (11 Bankhead-Coley, 6 King, and 11 Bella)** These awards focus on research with a focus on prevention and improved treatment or care delivery that contributes to a reduction in deaths in at least one of the following types of cancers: pediatric, lung, breast, prostate, colon, or melanoma.

**3 Awards – Technology Transfer: (3 Bankhead-Coley)** The goal of this grant mechanism is to stimulate technology transfer activities for promising research discoveries that could lead to innovations in the prevention, diagnosis, treatment, and/or cure of cancer and strengthen a project's economic feasibility and commercialization prospects.

**1 Awards – Disproportionately Impacted Populations: (1 King)** This research contributes to reductions in deaths due to the cancers.


**1 Award – Screening: (1 Bankhead-Coley)** This research priority focuses on improving screening accuracy, detection of high-risk subgroups, and/or improved implementation of a cancer screening program that results in an increase in early detection or prevention of at least one of the cancers listed above.

**4 Awards – Treatment-Related Morbidities: (1 Bankhead-Coley, 1 King, and 2 Bella)** This priority expands upon research that improves scientific understanding of causes and subsequent impact of cancer/cancer-treatment related morbidities in other systems.


**1 Award – Tobacco Use: (1 King)** The goal of this mechanism is to reduce tobacco use in children, adolescents, and adults.

*\*\* There were no awards in the categories of IND or IDE and the impact of obesity on cancer.*


# Bankhead-Coley Applications and Funded Projects



# King Applications and Funded Projects



# Live Like Bella Applications and Funded Projects





# The Florida Cancer Centers of Excellence Designation

Established in 2013 by the Florida Legislature, the Cancer Center of Excellence Designation (**381.925, FS**) recognizes hospitals, treatment centers, and other providers that demonstrate excellence in patient-centered coordinated care for persons undergoing cancer treatment and therapy in Florida.

Cancer Center of Excellence Webpage (<https://www.floridahealth.gov/provider-and-partner-resources/research/cancer-center-of-excellence-award.html>)

# Current Cancer Centers of Excellence

- Moffitt Cancer Center
- University of Miami Sylvester Cancer Center
- University of Florida Shands Hospital and Orlando Regional Medical Center
- Mayo Clinic Jacksonville
- Memorial Cancer Institute Florida Atlantic University
- Cleveland Clinic Florida- NEW as of 9/1/22

# Joint Committee for the Florida Cancer Centers of Excellence Program

The Joint Committee, consisting of 13 members (7 from CCRAB, 6 from BRAC) is required to:

1. develop rigorous performance measures, a rating system, and a rating standard that must be achieved to document and distinguish a cancer center that excels in providing quality, comprehensive, and patient-centered coordinated care.
2. Review at least every 3 years and revise, if applicable, the performance measures, rating system, and rating standard to ensure providers are continually enhancing their programs to reflect best practices and advances in cancer treatment and care from the perspective of quality, comprehensive, and patient-centered coordinated care.

Performance Measures and Rating System: ([https://www.floridahealth.gov/provider-and-partner-resources/research/CCEManual\\_PerformanceMeasures2019.pdf](https://www.floridahealth.gov/provider-and-partner-resources/research/CCEManual_PerformanceMeasures2019.pdf))

The Florida Cancer Control and Research Advisory Council and the Biomedical Research Advisory Council will review and approve prior to the evaluation of any provider under such criteria.

# Joint Committee for the Florida Cancer Centers of Excellence Program

The Joint Committee met on January 11<sup>th</sup>, 2023 to review and discuss potential changes to the **Performance Measures, Rating System, and Rating Standard Manual**, as well as the **Re-Designation Manual** for the Cancer Centers of Excellence Program.

Minor changes were made to include additional language addressing **quality assurance** and **safety improvements**:

Cancer Center of Excellence Performance Measures, Rating System, and Rating

1.6 The organization **demonstrates an active program of quality and safety improvement**, adopts and implements a continuous comprehensive quality indicator system, reports at a minimum annually on quality metrics, and makes a summary of the evaluation available to prospective patients and family members

1.7 When conducting cancer research, the organization must have an accredited human

Cancer Center of Excellence Performance Measures, Rating System, and Rating

**1.7 The organization demonstrates an active program of quality and safety improvement, adopts and implements a continuous comprehensive quality indicator system, reports at a minimum annually on quality metrics, and makes a summary of the evaluation available to prospective patients and family members.**

**Explanation**  
Adopting a continuous comprehensive quality indicator system is associated with improved

b. Tumor boards and treatment plan review

c. Highlight the clinical trials that your organization is conducting that exemplify cancer research. Indicate research accruals to clinical trial. Include demographic information on research participants. Submit information in Cancer Center Support Grant (CCSG) DT3 and DT4 tables. Follow this link to guidance on table formatting.  
<https://cancercenters.cancer.gov/Documents/CCSGDataGuide508C.pdf>

d. Availability of **Outcomes data, including areas of program enhancement involving patient safety and quality assurance standards must be easily accessible** on the organization's website. (Provide organization's link to online location).

- Overview of Performance Measures: Area I; Section 6; Page 4

- Performance Measures: Area I; Section 7; Page 14

- Re-Designation Manual: Area II; Section II.2,a; Page 4

# Joint Committee for the Florida Cancer Centers of Excellence Program: CCRAB Action Items

- Review and approve the Joint Committee and BRAC approved recommended additions to the Performance Measures and Re-Designation Manuals.
- Future Consideration: The joint committee also discussed the potential to include more specific and exacting standards for quality assurance (akin to QOPI or ASCO) in future evaluations of the Performance Measures.

# Contact Information



Vice Chair, Biomedical Research Advisory Council

Richard Nowakowski, PhD

850-644-9219

[richard.nowakowski@med.fsu.edu](mailto:richard.nowakowski@med.fsu.edu)

Program Contact:

Christine Kucera, Grant Manager

Biomedical Research

(850) 901-6374

[Christine.Kucera@flhealth.gov](mailto:Christine.Kucera@flhealth.gov)

Bonnie Gaughan-Bailey

Deputy Director, Public Health Research

850-558-9620

[Bonnie.Gaughan-Bailey@flhealth.gov](mailto:Bonnie.Gaughan-Bailey@flhealth.gov)